Therapeutic Advances In Musculoskeletal Disease Launched By SAGE

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics;  Biology / Biochemistry
Article Date: 23 Oct 2009 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:5 stars

5 (1 votes)


SAGE has announced the launch of Therapeutic Advances in Musculoskeletal Disease, the latest in SAGE's highly-regarded Therapeutic Advances series.

Therapeutic Advances in Musculoskeletal Disease is for all professionals concerned with research into, and the practice of, musculoskeletal disease and is a forum for all views on related subjects. The journal offers rapid peer review and publication, with manuscripts published online within 7 weeks of acceptance.

The editors welcome original research and review articles of latest advances in the treatment of arthropathies and other joint disorders, systemic connective tissue disorders, dorsopathies, soft tissue disorders, osteopathies and chondropathies.

Editor in Chief, Philip Sambrook OAM, has published over 270 peer reviewed papers including invited editorials in the New England Journal of Medicine, British Medical Journal and The Lancet. In addition he is the current President of the Australian & New Zealand Bone & Mineral Society, on the Committee of Scientific Advisors of The International Osteoporosis Foundation, and on the Board of the International Bone and Mineral Society.

"Musculoskeletal disease is affecting an increasing proportion of our ageing population - the chronic diseases it includes have led to many new categories of medical treatments that are changing the way we manage patients," said Philip Sambrook. "While there are many journals in this growing area, my feeling is that we still need to have more avenues to publish and access the material. For this reason, I am enthusiastic about leading the launch of this new journal."

Therapeutic Advances in Musculoskeletal Disease is the seventh journal to be launched within the Therapeutic Advances series. Each journal publishes six issues per year and will be freely available on the award-winning SAGE Journals Online platform for the first three years of publication.

"We're delighted to be working with such a distinguished Editor in Chief and editorial board to continue the successful growth of the Therapeutic Advances series," said Tessa Picknett, Publisher, STM journals. "Launching new journals continues to become more challenging, but the impact that this series has made indicates there is still demand for access to timely peer reviewed content across therapeutic treatments."

Source:
Mithu Lucraft
SAGE Publications UK

Article adapted by Medical News Today from original press release.
Visit our arthritis / rheumatology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Mithu Lucraft. "Therapeutic Advances In Musculoskeletal Disease Launched By SAGE." Medical News Today. MediLexicon, Intl., 23 Oct. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/168398.php>

APA
Mithu Lucraft. (2009, October 23). "Therapeutic Advances In Musculoskeletal Disease Launched By SAGE." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/168398.php.

Please note: If no author information is provided, the source is cited instead.




Arthritis / Rheumatology

What is Rheumatoid Arthritis?

Rheumatoid arthritis, sometimes referred to as rheumatoid disease, is a chronic (long lasting), progressive and disabling autoimmune disease that causes inflammation (swelling) and pain in the joints, the tissue around the joints, and other organs in... Read more...

Most Popular Articles





Follow Our Arthritis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Arthritis / Rheumatology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »